Gene therapy for head and neck cancer

Current Opinion in Oncology

Volumn 8, Issue 3, 1996, Pages 227-231

  Breau, Randall L ^a   Clayman, Gary L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; GENE THERAPY; HEAD AND NECK CANCER; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0029891318     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199605000-00010     Document Type: Review

References (33)

1. Cancer Facts and Figures. Washington, DC: American Cancer Society; 1990. (publication no. 90-425, M. No. 5008-LE.)
2. Whitaker DC: Clinical Evaluation of Tumors of the Skin, vol 2. In Comprehensive Management of Head and Neck Tumors. Edited by Thawley SE, Panje WR. Philadelphia: WB Saunders; 1987:1158-1172.
3. O'Malley BW Jr, Ledley FD: Somatic gene therapy: methods for the present and future. Arch Otolaryngol Head Neck Surg 1993, 119:1100-1107.
4. Liu TJ, El-Naggar AK, McDonnell TJ, Steck KD, Wang M, Taylor DL, Clayman GL: Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res 1995, 55:3117-3122. The authors suggest that wt-p53 plays an important role in the induction of apoptosis in human head and neck cancer cell lines, and that selective induction of apoptosis in cancer cells may be important as a future treatment strategy in cancer gene therapy.
5. Gangandeep SP, Poston GJ, Kinsella AR: Gene therapy in surgical oncology. Ann Surg Oncol 1995, 2:179-188. This paper is an excellent overview of the use of gene therapy in surgical oncology. It presents a concise look at the potential applications of molecular biology for practicing oncologists.
6. Trojan J, Blossey BK, Johnson TR, Rudin SR, Tykocinski M, Ilan J, Ilan J: Loss of tumorigenicity of rat glioblastoma directed by episome based antisense cDNA transcription of insulin-like growth factor I. Proc Natl Acad Sci U S A 1992, 89:4874-4878.
7. Chen J, Yee JK, Yeargin J, Friedman T, Haas M: Suppression of acute lymphoblastic leukaemia by the human wild-type p53 gene. Cancer Res 1992, 52:222-226.
8. Pardoll D: Immunotherapy with cytokine gene transduced tumor cells: the next wave in gene therapy for cancer. Curr Opin Oncol 1992, 4:1124-1129.
9. Huber BE, Richards CA, Kretritsky TA: Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma. Proc Natl Acad Sci U S A 1991, 88:8039-8043.
10. Kozarsky KF, Wilson JM: Gene therapy: adenovirus vectors. Curr Opin Genet Dev 1993, 3:499-503.
11. Varmus HE: Retroviruses. Science 1988, 240:1427-1435.
12. McLachlin JR, Cornetta K, Eglitis MA, Anderson WF: Retroviral-mediated gene transfer. Prog Nucl Acid Res Mol Biol 1990, 38:91-135.
13. Markowtiz D, Goff S, Bank A: A safe packaging line for gene transfer: separating viral genes on two different plasmids. J Virol 1988, 62:1120-1124.
14. Miller DG, Adam MA, Miller AD: Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990, 10:4239-4242.
15. Liu TJ, Zhang WW, Taylor DL, Roth JA, Goepfert H, Clayman GL: Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res 1994, 54:3662-3667. This paper was the initial study to appear in the head and neck literature demonstrating growth suppression of human head and neck cancer cell lines by using a gene insertion approach. The authors used a replication-deficient adenovirus to introduce a wild-type p53 gene into cancer cell lines. The importance of the adenoviral vector as a delivery system was also emphasized.
16. Mulligan RC: The basic science of gene therapy. Science 1993, 260:926-932.
17. Mittal SK, McDermott MR, Johnson DC, Prevec L, Graham FL: Monitoring foreign gene expression by a human adenovirus-based vector using the firefly luciferase gene as a reporter. Virus Res 1993, 28:67-90.
18. Yei S, Mittereder N, Tang K: Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung. Gene Ther 1994, 1:192-200.
19. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM: Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A 1994, 91:4407-4411.
20. Clayman GL, Trapnell BC, Mittereder N, Liu TJ, Eicher S, Zhang S, Shilolitoe EJ: Transduction of normal and malignant oral epithelium by an adenovirus vector: the effect of dose and treatment time on transduction efficiency and tissue penetration. Cancer Gene Ther 1995, 2:105-111.
21. Clayman GL, El-Naggar AK, Roth JA, Zhang WW, Goepfert H, Taylor DL, Liu TJ: In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck sqamous carcinoma. Cancer Res 1995, 55:1-6. This paper demonstrates a microscopic residual model that mimics the postsurgical environment of head and neck cancer patients with advanced disease. These results allow further development of molecular therapy for head and neck cancer and other solid malignancies.
22. Martinez J, Georgoff I, Martinez J, Levine AJ: Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev 1991, 5:151-159.
23. Diller L, Kassell J, Nelson CE, Gryka MA, Litwak G, Gebhardt M, Bressac B, Ozturk M, Baker SJ, Vogelstein B, Friend S: p53 Functions as a cell cycle control protein in osteosarcoma. Mol Cell Biol 1990, 10:5772-5781.
24. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994, 264:436-440.
25. Nobori T, Miura K, Wu DJ, Lois A, Tabayashi K, Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994, 370:753-756.
26. Spruck CH III, Gonzalez-Zulueta M, Shibata A, Simoneau AR, Lin MF, Gonzalez F, Tsai YC, Jones PA: p16 Gene in uncultured tumors. Nature 1994, 370:183-184.
27. Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, Tokino K, Van der Riet P, Blaugrund JE, Sidransky D: Rates of p16 (MTST1) mutations in primary tumors with 9p loss. Science 1994, 265:415-416.
28. Mori T, Miura K, Aoki T, Nishihira T, Mori S, Nakamura Y: Frequent somatic mutations of the MTST1/CDK4 gene in esophageal squamous cell carcinoma. Cancer Res 1994, 54:3396-3397.
29. O'Malley BW Jr, Chen SH, Schwartz MR, Woo SLC: Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. Cancer Res 1995, 55:1080-1085. The authors demonstrated the suppression of tumor development in a nude mouse model using a replication-defective recombinant adenovirus containing the herpes simplex virus thymidine kinase gene.
30. O'Malley BW Jr, Ledley FD: Somatic gene therapy in otolaryngology-head and neck surgery. Arch Otolaryngol Head Neck Surg 1993, 119:1191-1197.
31. Townsend SE, Allison JP: Tumor rejection after costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993, 259:368-370.
32. Rosenberg SA: Immunotherapy and gene therapy of cancer. Cancer Res 1991, 51(suppl 18):5074-5079.
33. Rosenberg SA: Gene therapy for cancer. JAMA 1992, 268:2416-2419.